[go: up one dir, main page]

BRPI0516378A - inibição por rnai de soro amilóide a para tratamento de glaucoma - Google Patents

inibição por rnai de soro amilóide a para tratamento de glaucoma

Info

Publication number
BRPI0516378A
BRPI0516378A BRPI0516378-1A BRPI0516378A BRPI0516378A BR PI0516378 A BRPI0516378 A BR PI0516378A BR PI0516378 A BRPI0516378 A BR PI0516378A BR PI0516378 A BRPI0516378 A BR PI0516378A
Authority
BR
Brazil
Prior art keywords
glaucoma
treatment
serum
rna inhibition
inhibition
Prior art date
Application number
BRPI0516378-1A
Other languages
English (en)
Inventor
Abbot F Clark
Wan-Heng Wang
Loretta Mcnatt
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0516378A publication Critical patent/BRPI0516378A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIçãO POR RNAi DE SORO AMILóIDE A PARA TRATAMENTO DE GLAUCOMA. A presente invenção refere-se a uma interferência por RNA para inibição de expressão AmRNA de soro amilóide em glaucomas que envolvem expressão de SAA.
BRPI0516378-1A 2004-12-23 2005-12-19 inibição por rnai de soro amilóide a para tratamento de glaucoma BRPI0516378A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63870604P 2004-12-23 2004-12-23
PCT/US2005/046436 WO2006071691A2 (en) 2004-12-23 2005-12-19 Rnai inhibition of serum amyloid a for treatment of glaucoma

Publications (1)

Publication Number Publication Date
BRPI0516378A true BRPI0516378A (pt) 2008-09-02

Family

ID=36440864

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516378-1A BRPI0516378A (pt) 2004-12-23 2005-12-19 inibição por rnai de soro amilóide a para tratamento de glaucoma

Country Status (18)

Country Link
US (7) US20060172961A1 (pt)
EP (1) EP1831369B1 (pt)
JP (3) JP2008525469A (pt)
KR (1) KR101311275B1 (pt)
CN (2) CN102172407A (pt)
AR (1) AR051848A1 (pt)
AU (1) AU2005322228B2 (pt)
BR (1) BRPI0516378A (pt)
CA (1) CA2591403A1 (pt)
DK (1) DK1831369T3 (pt)
ES (1) ES2393325T3 (pt)
MX (1) MX2007007388A (pt)
PL (1) PL1831369T3 (pt)
PT (1) PT1831369E (pt)
SI (1) SI1831369T1 (pt)
TW (1) TWI401316B (pt)
WO (1) WO2006071691A2 (pt)
ZA (1) ZA200704936B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598234A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
KR20100061792A (ko) * 2007-10-01 2010-06-09 알콘 리서치, 리미티드 안 질환을 치료 또는 예방하기 위한 간섭 ｒｎａ 분자의 자기-상보적 ａａｖ 매개 전달
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
AR069328A1 (es) 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
EP3584320A1 (en) 2008-09-25 2019-12-25 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
WO2012161677A1 (en) 2011-05-20 2012-11-29 Alcon Research, Ltd. TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
US20130178421A1 (en) 2012-01-06 2013-07-11 Alcon Research, Ltd. Interfering rna delivery system and uses thereof
US10611819B2 (en) 2014-07-15 2020-04-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated polypeptides of CD44 and uses thereof
US20250352666A1 (en) 2022-06-07 2025-11-20 Generation Bio Co. Lipid nanoparticle compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6326193B1 (en) * 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
PL208368B1 (pl) * 2000-02-29 2011-04-29 Alcon Inc Sposób diagnozowania jaskry
JP2003526367A (ja) * 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
NZ522045A (en) * 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
US6455308B1 (en) * 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US20040072181A1 (en) * 2002-01-22 2004-04-15 Whitehead Alexander Steven Methods for determining drug responsiveness
US7091333B2 (en) * 2002-03-27 2006-08-15 Aegera Therapeutics, Inc. Antisense IAP nucleobase oligomers and uses thereof
DK1504126T3 (da) * 2002-05-03 2014-06-10 Univ Duke Fremgangsmåde til regulering af genekspression
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003261449A1 (en) * 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
AU2003264727A1 (en) * 2002-09-04 2004-03-29 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
US20050137122A1 (en) * 2003-12-17 2005-06-23 Alcon, Inc. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7718697B2 (en) * 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease

Also Published As

Publication number Publication date
US20100152279A1 (en) 2010-06-17
ZA200704936B (en) 2008-10-29
ES2393325T3 (es) 2012-12-20
WO2006071691A2 (en) 2006-07-06
US20060172961A1 (en) 2006-08-03
US20140357692A1 (en) 2014-12-04
WO2006071691A3 (en) 2006-11-16
CN101124322A (zh) 2008-02-13
JP2012193209A (ja) 2012-10-11
US20150225720A1 (en) 2015-08-13
SI1831369T1 (sl) 2013-01-31
JP2008525469A (ja) 2008-07-17
KR101311275B1 (ko) 2013-09-27
CN101124322B (zh) 2011-12-14
PL1831369T3 (pl) 2013-07-31
US20120122961A1 (en) 2012-05-17
AU2005322228A1 (en) 2006-07-06
KR20070093118A (ko) 2007-09-17
TW200634153A (en) 2006-10-01
CN102172407A (zh) 2011-09-07
TWI401316B (zh) 2013-07-11
US20110054008A1 (en) 2011-03-03
US20130123337A1 (en) 2013-05-16
JP2015044858A (ja) 2015-03-12
CA2591403A1 (en) 2006-07-06
AR051848A1 (es) 2007-02-14
EP1831369A2 (en) 2007-09-12
PT1831369E (pt) 2012-12-06
AU2005322228B2 (en) 2011-08-11
MX2007007388A (es) 2007-08-23
EP1831369B1 (en) 2012-09-19
DK1831369T3 (da) 2012-10-08
WO2006071691A8 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
MX2010004454A (es) Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
BR112013031032A2 (pt) inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
MA32934B1 (fr) Combinaisons inhibitrices hsp90
PL2049132T3 (pl) Nowe środki do leczenia zaburzeń związanych z osłabionym neuroprzekaźnictwem
PT2359834T (pt) Tratamento de doentes com hemoglobimúria paroxística noturna por meio de um inibidor de complemento
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
DK2032163T3 (da) Multidoseringsplan for en adjuvant-sparende influenzavaccination
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
UA108887C2 (xx) Кристалічна форма бензил-бензольного інгібітора sglt2
EP2001461A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
DK1993589T3 (da) Behandlinger for neurologiske sygdomme
BRPI0516378A (pt) inibição por rnai de soro amilóide a para tratamento de glaucoma
EP2035024A4 (en) TREATMENT AND PREVENTION OF PANCREATIC CANCER WITH DELTA TOCOTRIENOL
BRPI0722060A2 (pt) Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
EP1865955A4 (en) METHOD FOR TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND ALPHA REDUCTASE INHIBITORS
SV2009003286A (es) Sal de potasio cristalina de analogos de lipoxina a4
EP2225196A4 (en) CYSTONE PROTEASE INHIBITOR FOR THE TREATMENT OF PARASITIC DISEASES
MX2011004870A (es) Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
DOP2005000010A (es) Inhibidores de quinasa
WO2010042530A3 (en) Nlrc5 as a target for immune therapy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]